Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel

Research output: Contribution to journalArticle

Standard

Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel. / Dawood, Ban B; Lowe, Gillian C; Lordkipanidzé, Marie; Bem, Danai; Daly, Martina E; Makris, Mike; Mumford, Andrew; Wilde, Johnathan; Watson, Steve P.

In: Blood, Vol. 120, No. 25, 13.12.2012, p. 5041-5049.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{a0553f1ffbb1410695bdd495928c3ab4,
title = "Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel",
abstract = "Light transmission aggregometry (LTA) is used worldwide for the investigation of heritable platelet function disorders (PFD), but interpretation of results is complicated by the feedback effects of ADP and thromboxane A(2) and by the overlap with the response of healthy volunteers. Over 5 years, we have performed lumi-aggregometry to nine platelet agonists in 111 unrelated research participants with suspected PFDs and in 70 healthy volunteers. Abnormal LTA or ATP secretion test results were identified in 58% of participants. In 84% of these, the patterns of response were consistent with defects in Gi receptor signalling, the thromboxane pathway and dense granule secretion. Participants with defects in signalling to Gq-coupled receptor agonists and to collagen were also identified. Targeted genotyping identified three participants with function disrupting mutations in the P2Y(12) ADP and thromboxane receptors. Our study illustrates that detailed phenotypic analysis using LTA and ATP secretion is a powerful tool for diagnosis of PFDs and enables subdivision at the level of platelet signaling pathways and in some cases to individual receptors. We further demonstrate that most PFD can be reliably diagnosed using a streamlined panel of key platelet agonists and specified concentrations suitable for testing in most clinical diagnostic laboratories.",
author = "Dawood, {Ban B} and Lowe, {Gillian C} and Marie Lordkipanidz{\'e} and Danai Bem and Daly, {Martina E} and Mike Makris and Andrew Mumford and Johnathan Wilde and Watson, {Steve P}",
year = "2012",
month = dec
day = "13",
doi = "10.1182/blood-2012-07-444281",
language = "English",
volume = "120",
pages = "5041--5049",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "25",

}

RIS

TY - JOUR

T1 - Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel

AU - Dawood, Ban B

AU - Lowe, Gillian C

AU - Lordkipanidzé, Marie

AU - Bem, Danai

AU - Daly, Martina E

AU - Makris, Mike

AU - Mumford, Andrew

AU - Wilde, Johnathan

AU - Watson, Steve P

PY - 2012/12/13

Y1 - 2012/12/13

N2 - Light transmission aggregometry (LTA) is used worldwide for the investigation of heritable platelet function disorders (PFD), but interpretation of results is complicated by the feedback effects of ADP and thromboxane A(2) and by the overlap with the response of healthy volunteers. Over 5 years, we have performed lumi-aggregometry to nine platelet agonists in 111 unrelated research participants with suspected PFDs and in 70 healthy volunteers. Abnormal LTA or ATP secretion test results were identified in 58% of participants. In 84% of these, the patterns of response were consistent with defects in Gi receptor signalling, the thromboxane pathway and dense granule secretion. Participants with defects in signalling to Gq-coupled receptor agonists and to collagen were also identified. Targeted genotyping identified three participants with function disrupting mutations in the P2Y(12) ADP and thromboxane receptors. Our study illustrates that detailed phenotypic analysis using LTA and ATP secretion is a powerful tool for diagnosis of PFDs and enables subdivision at the level of platelet signaling pathways and in some cases to individual receptors. We further demonstrate that most PFD can be reliably diagnosed using a streamlined panel of key platelet agonists and specified concentrations suitable for testing in most clinical diagnostic laboratories.

AB - Light transmission aggregometry (LTA) is used worldwide for the investigation of heritable platelet function disorders (PFD), but interpretation of results is complicated by the feedback effects of ADP and thromboxane A(2) and by the overlap with the response of healthy volunteers. Over 5 years, we have performed lumi-aggregometry to nine platelet agonists in 111 unrelated research participants with suspected PFDs and in 70 healthy volunteers. Abnormal LTA or ATP secretion test results were identified in 58% of participants. In 84% of these, the patterns of response were consistent with defects in Gi receptor signalling, the thromboxane pathway and dense granule secretion. Participants with defects in signalling to Gq-coupled receptor agonists and to collagen were also identified. Targeted genotyping identified three participants with function disrupting mutations in the P2Y(12) ADP and thromboxane receptors. Our study illustrates that detailed phenotypic analysis using LTA and ATP secretion is a powerful tool for diagnosis of PFDs and enables subdivision at the level of platelet signaling pathways and in some cases to individual receptors. We further demonstrate that most PFD can be reliably diagnosed using a streamlined panel of key platelet agonists and specified concentrations suitable for testing in most clinical diagnostic laboratories.

U2 - 10.1182/blood-2012-07-444281

DO - 10.1182/blood-2012-07-444281

M3 - Article

C2 - 23002116

VL - 120

SP - 5041

EP - 5049

JO - Blood

JF - Blood

SN - 0006-4971

IS - 25

ER -